Commonwealth Equity Services LLC Cuts Holdings in AbbVie Inc. $ABBV

Commonwealth Equity Services LLC lessened its position in shares of AbbVie Inc. (NYSE:ABBV) by 6.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,130,248 shares of the company’s stock after selling 74,586 shares during the period. Commonwealth Equity Services LLC owned approximately 0.06% of AbbVie worth $261,698,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Endeavor Private Wealth Inc. acquired a new position in AbbVie during the third quarter valued at approximately $298,000. Earned Wealth Advisors LLC boosted its position in AbbVie by 19.5% during the 3rd quarter. Earned Wealth Advisors LLC now owns 3,741 shares of the company’s stock worth $866,000 after purchasing an additional 610 shares during the period. Asset Management One Co. Ltd. increased its holdings in AbbVie by 1.7% in the 3rd quarter. Asset Management One Co. Ltd. now owns 870,132 shares of the company’s stock valued at $201,470,000 after purchasing an additional 14,595 shares in the last quarter. Gateway Investment Advisers LLC raised its position in AbbVie by 0.9% in the third quarter. Gateway Investment Advisers LLC now owns 372,051 shares of the company’s stock valued at $86,145,000 after purchasing an additional 3,230 shares during the period. Finally, Fifth Third Wealth Advisors LLC lifted its stake in shares of AbbVie by 1.9% during the third quarter. Fifth Third Wealth Advisors LLC now owns 47,505 shares of the company’s stock worth $10,999,000 after purchasing an additional 889 shares in the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Stock Up 0.3%

NYSE:ABBV opened at $229.26 on Monday. The company has a market cap of $405.19 billion, a PE ratio of 173.68, a P/E/G ratio of 0.96 and a beta of 0.36. The business’s 50 day moving average is $226.69 and its two-hundred day moving average is $214.14. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business’s revenue was up 9.1% compared to the same quarter last year. During the same period in the prior year, the company posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, sell-side analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is currently 496.97%.

Wall Street Analyst Weigh In

Several brokerages recently commented on ABBV. Wells Fargo & Company raised their target price on AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a report on Friday, September 12th. Citigroup dropped their price target on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a research note on Monday, November 3rd. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and upped their price objective for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. Erste Group Bank lowered AbbVie from a “buy” rating to a “hold” rating in a research report on Tuesday, October 14th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a report on Wednesday, October 8th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $245.84.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.